Profound thrombocytopenia following tirofiban administration remains a rare but significant complication in ischemic stroke management. Remarkably, the deficiency manifested after subsequent treatment. The immune-mediated pathogenesis has been described but remains incompletely understood.
While tirofiban has demonstrated efficacy and a favorable safety profile in acute ischemic stroke, clinicians should remain vigilant for rare but serious adverse events. This case highlights the need for further research to clarify patient-specific risk factors, optimal monitoring strategies, and management protocols for tirofiban-induced thrombocytopenia.